This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Retinal Nerve Fibres Layers Thickness Study in Glaucomatous Patients

This study has been completed.
vingolo enzo maria
domanico daniela
salvatore serena
Information provided by:
University of Roma La Sapienza Identifier:
First received: November 29, 2010
Last updated: December 3, 2010
Last verified: August 2009
In this study the investigators are going to study the retinal nerve fibers layers (RNFL) modification of two groups of patients, one taking no drugs, the other taking forskolin, rutin and vitamins B1 and B2.

Condition Intervention
Glaucoma Drug: forskolin, rutin and vitamins B1 and B2

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by University of Roma La Sapienza:

Primary Outcome Measures:
  • retinal nerve fibres layer thickness

Secondary Outcome Measures:
  • global risk threshold for glaucoma progression


Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Age (30-80 years);
  • Baseline Intraocular pressure (IOP) (20-32 mmHg): average untreated Intra Ocular Pressure (IOP) for both eyes as determined from 2 to 4 visits within a 6-months period;
  • Central Corneal Thickness (CCT) (475-650 µm): average of 3 different measurements from both eyes during the same visit;
  • Pattern standard deviation (PSD) (0,50-3,00 dB) average of both eyes as stated on the most recent visual field index report
  • Vertical Cup/Disk ratio (0,00-0,80): average of both eyes
  • All these data were entered into a calculator specially designed for STAR (Scoring Tool for assessing risk) II parameter. The patients were divided into low-, moderate- and high risk groups according to the result given by the calculator.

Exclusion Criteria:

-other ocular pathologies than glaucoma

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01254006

Univerisity La Sapienza
Latina, Italy
Sponsors and Collaborators
University of Roma La Sapienza
vingolo enzo maria
domanico daniela
salvatore serena
  More Information Identifier: NCT01254006     History of Changes
Other Study ID Numbers: GLA0110
Study First Received: November 29, 2010
Last Updated: December 3, 2010

Additional relevant MeSH terms:
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on September 25, 2017